Cardiff Oncology, Inc.

NasdaqCM:CRDF Lagerbericht

Marktkapitalisierung: US$58.2m

Cardiff Oncology Management

Management Kriterienprüfungen 2/4

Cardiff Oncology CEO ist Mani Mohindru , ernannt in Jan 2026, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.086% der Aktien des Unternehmens, im Wert von $50.26K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 0.5 Jahre bzw. 11.9 Jahre.

Wichtige Informationen

Mani Mohindru

Geschäftsführender

US$183.7k

Gesamtvergütung

Prozentsatz des Geschäftsführergehaltsn/a
Amtszeit als Geschäftsführerless than a year
Eigentum des Geschäftsführers0.09%
Durchschnittliche Amtszeit des Managementsless than a year
Durchschnittliche Amtszeit der Vorstandsmitglieder11.9yrs

Jüngste Management Updates

Recent updates

Seeking Alpha • Jun 27

Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity

Summary Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. The new CMO's pedigree suggests confidence in the company's prospects ahead of the catalyst. The delay could suggest an attempt to improve poor data, or an ability to add to already strong data by waiting for more patient second scans. Short interest is high, increasing volatility and squeeze potential if trial data is strong, but also signaling caution from sophisticated investors. CRDF's cash runway is sufficient for the near-term catalyst; I hold call options expecting momentum to return, as the July 29th readout date approaches. Read the full article on Seeking Alpha
Analyseartikel • May 21

Is Cardiff Oncology (NASDAQ:CRDF) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Feb 18

Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage. Despite high risks, Cardiff's cash runway and positive clinical data justify a "Strong Buy" rating for high-risk tolerant long-term investors. Read the full article on Seeking Alpha
Seeking Alpha • Dec 12

Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning

Summary Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk. Despite uncertainties, I maintain a Buy rating, anticipating onvansertib's potential to significantly impact first-line RAS-mutant mCRC therapy. Read the full article on Seeking Alpha
Seeking Alpha • Nov 07

Cardiff Oncology: Some Data Are In; Here's What You Should Know And Look For Next

Summary Cardiff Oncology's main focus is onvansertib, a PLK1 inhibitor, showing promise in metastatic colorectal cancer, especially in bevacizumab-naive patients. CRDF-004 phase 2 trial's results are crucial for Cardiff's future, with data expected within two months, potentially informing a pivotal phase 3 trial. Financially, Cardiff has a cash runway of 5-6 quarters, but will need additional funding, potentially leading to significant shareholder dilution. While optimistic about onvansertib's potential, I caution investors due to the high-risk nature and uncertain outcomes of the upcoming trial results. Read the full article on Seeking Alpha
Analyseartikel • Oct 09

We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 04

Cardiff Oncology: Paramount Data Imminent In Huge First-Line mCRC Market

Summary Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated metastatic colorectal cancer, potentially opening a massive market with an estimated $567 million to $3.78 billion in annual US sales. Onvansertib has demonstrated superior efficacy and safety over historical controls and competitors, particularly in bevacizumab-naïve patients, with impressive objective response rates and progression-free survival. Positive data from the ongoing CRDF-004 trial could lead to significant upside for Cardiff, attracting potential partnerships or acquisition interest from big pharma, including Pfizer. Cardiff's strong financial position, low cash burn, and favorable analyst ratings make it a compelling buy, with substantial growth potential in the mCRC market and beyond. Read the full article on Seeking Alpha
Analyseartikel • Jun 19

We're Hopeful That Cardiff Oncology (NASDAQ:CRDF) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Mar 09

Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)

Summary Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial. Read the full article on Seeking Alpha
Analyseartikel • Mar 03

We're Not Very Worried About Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analyseartikel • Nov 16

Here's Why We're Watching Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Geschäftsführer

Mani Mohindru (54 yo)

less than a year
Amtszeit
US$183,670
Vergütung

Dr. Mani Mohindru, Ph D., is Co-Founder, President and Director of Roshon Therapeutics. She had been Interim Chief Executive Officer at Cardiff Oncology, Inc. since January 27, 2026 until April 09, 2026 an...

Führungsteam

NamePositionAmtszeitVergütungEigentümerschaft
Mani Mohindru
Presidentless than a yearUS$183.67k0.086%
$ 50.3k
Roger Sidhu
Chief Medical Officer1.1yrsUS$2.47m0%
$ 0
Josh Muntner
Chief Financial Officerless than a yearkeine Daten0.00073%
$ 424.7
Ajay Aggarwal
Chief Operating Officerless than a yearkeine Datenkeine Daten
Brigitte Lindsay
Chief Accounting Officerless than a yearkeine Daten0.040%
$ 23.3k
Tod Smeal
Chief Scientific Officer4.5yrsUS$4.17mkeine Daten
Elizabeth Anderson
VP of Finance & Administration11yrskeine Datenkeine Daten
0.5yrs
Durchschnittliche Betriebszugehörigkeit
57yo
Durchschnittliches Alter

Erfahrenes Management: CRDFDas Führungsteam des Unternehmens gilt nicht als erfahren ( 0.5 Jahre durchschnittliche Betriebszugehörigkeit), was auf ein neues Team schließen lässt.

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Mani Mohindru
President5.1yrsUS$183.67k0.086%
$ 50.3k
Charles Cantor
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Gary Pace
Independent Director6.3yrsUS$184.17k3.02%
$ 1.8m
K. Hirth
Member of Scientific Advisory Board11.9yrskeine Datenkeine Daten
Paul Billings
Member of Scientific Advisory Board13.7yrsUS$35.85kkeine Daten
Rodney Markin
Independent Chairman of the Board12.4yrsUS$225.67k0.045%
$ 26.4k
Carlo Croce
Member of Scientific Advisory Boardno datakeine Datenkeine Daten
Riccardo Dalla-Favera
Member of Scientific Advisory Board16.3yrskeine Datenkeine Daten
Lale White
Independent Director6.3yrsUS$189.17k0.17%
$ 96.8k
Alberto Bardelli
Member of Scientific Advisory Board11.8yrskeine Datenkeine Daten
Renee Tannenbaum
Independent Director5.1yrsUS$181.67k0.029%
$ 17.0k
Brunangelo Falini
Member of Scientific Advisory Board16.3yrskeine Datenkeine Daten
11.9yrs
Durchschnittliche Betriebszugehörigkeit
74yo
Durchschnittliches Alter

Erfahrener Vorstand: CRDFDie Vorstandsmitglieder sind sehr erfahren ( 11.9 ).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/07/31 12:44
Aktienkurs zum Tagesende2026/07/31 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Cardiff Oncology, Inc. wird von 14 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Paul KnightBrean Capital Historical (Janney Montgomery)
Bryan BrokmeierCantor Fitzgerald & Co.
Gum-Ming LoweCraig-Hallum Capital Group LLC